Immuron Ltd — Regulatory Filings 2013

Jul 9, 2013

==> picture [199 x 43] intentionally omitted <==

ASX Announcement / Media Release

Wednesday 10[th] July 2013

Change of Registered Office

Immuron Limited [ASX: IMC] (the Company) wishes to advise that the Company has today moved the location of its Registered Office to the office of the Company Secretaries at:

Suite 1, 1233 High Street, Armadale, Victoria 3143 AUSTRALIA. Telephone: +61 (0)3 9824 5254 Facsimile: +61 (0)3 9822 7735

The office is open Monday to Friday 9:00am until 5:30pm Australian Eastern Standard Time excluding Public Holidays.

For and on behalf of the Company;

==> picture [105 x 41] intentionally omitted <==

Peter Vaughan Company Secretary Immuron Limited

About Immuron

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron’s products will be expedited. Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver/NASH, and influenza. Immuron has one product on the market, Travelan, for preventing travellers’ diarrhoea. Immuron’s main scientific alliances are with Hadassah Medical Centre (Israel), the University of Melbourne and Monash University (Australia).

Suite 1, 1233 High Street www.immuron.com Phone: + 61 (0)3 9824 5254 Armadale, Victoria 3143 Facsimile: + 61 (0)3 9822 7735 ABN: 80 063 114 045 AUSTRALIA